Prof Frank Bonner, Chief Executive Officer of SC4SM, presented at last year's Stem Cells USA & Regenerative Medicine Congress on the topic, âSuccessful exploitation of stem cell assays in predictive toxicology.'
In his presentation, Frank gives an overview on:
- What defines a fit-for-purpose cell? How far along are we to reaching fit-for-purpose cell production?
- Update on protocol refinement program to derive robust reproduction of a sufficient number of cells, with sufficient characteristics for drug discovery procedure
- Considering the next step: comparison of a hepatocyte stem cell assay with HepG2 cells to validate stem cell platforms as drug discovery tools
For up to date information on the stem cells and regenerative medicine market, register now for Stem Cells USA & Regenerative Medicine Congress.